Identification Of Risk Factors Of Bone Metastasis Among Iraqi Breast Cancer Women
DOI:
https://doi.org/10.62951/ijhm.v1i4.103Keywords:
Breast Neoplasms, Carcinoma, Quality of Life, Bone NeoplasmsAbstract
Background: The most common site of metastases in people with breast cancer is bone metastasis. Patients with advanced phases of cancer are associated with an increased prevalence of several types of metastases, one of which is bone metastasis. Object: Assessment of the risk factors for bone metastases in patients with breast cancer. Patients and Methods: This is a retrospective study of 316 patients with breast cancer who either had bone metastases at the time of diagnosis or developed it later on. The study was carried out between January 2013 and April 2018. Three hundred and sixteen patients were assigned into two groups. In the case group, 100 patients with breast cancer had been diagnosed with bone metastasis by CT, MRI, bone scan, and PET scan; in the control group, there were 216 cases in are control group with breast cancer metastasis to sites other than bone. The questionnaire was created to record all factors (with the exception of demographic information), such as age, histopathological reading for invasive lobular carcinoma, invasive ductal carcinoma, or another type of cancer, ER status, PR status, Her2neu status, lymph node status and stage, and menopausal status. Results: The majority were 45 years of age or younger, and 96.5% of them had invasive ductal carcinoma in terms of hormonal status. Positive ER and PR status is found in 67.7% and 67.1% of the cases, respectively; 40.5% of the cases had amplified Her2neu receptors, 78.5% of the cases had positive lymph nodes, and 41.9% of the cases had (N1) stage. The highest proportion of bone metastasis was associated with negative ER and PR receptors (46.2% and 49%, respectively), while no significant statistical association (P= 0.65). Conclusion: negative ER, PR status, and Her2neu receptors not amplified, lymph node involvement, age 45 and less, infiltrating lobular carcinoma (ILC) histological type, and menopausal state are significant risk factors for bone metastasis in breast cancer.
Downloads
References
Al-Hussaniy H, Al-Biati H. The Role of Leptin Hormone, Neuropeptide Y, Ghrelin and Leptin/Ghrelin ratio in Obesogenesis. Medical and Pharmaceutical Journal 2022; 1: 52–63.
Al-Hussaniy H, Altalebi RR, Tylor FM, et al. Leptin Hormone: In Brief. Medical and Pharmaceutical Journal 2022; 1: 1–3.
Al-Hussaniy H. The Effect of MicroRNA-409-3p for Treatment and Response to Tumor Proliferation of Lung Cancer Cell Lines (In Vitro). Asian Pacific Journal of Cancer Prevention: APJCP 2022; 23: 3151–3156.
Al-Hussaniy HA, Mohammed ZN, Alburghaif AH, et al. Panax ginseng as Antioxidant and Anti-inflammatory to reduce the Cardiotoxicity of Doxorubicin on rat module. Research Journal of Pharmacy and Technology 2022; 15: 4594–4600.
Ban J, Fock V, Aryee DNT, et al. Mechanisms, diagnosis and treatment of bone metastases. Cells 2021; 10: 2944.
Başdelioğlu K. Bone metastasis: evaluation of 1100 patients with breast cancer. Int J Clin Exp Pathol 2021; 14: 338–347.
Billena C, Wilgucki M, Flynn J, et al. 10-year breast cancer outcomes in women≤ 35 years of age. International Journal of Radiation Oncology* Biology* Physics 2021; 109: 1007–1018.
Celik Y, Talo M, Yildirim O, et al. Automated invasive ductal carcinoma detection based using deep transfer learning with whole-slide images. Pattern Recognit Lett 2020; 133: 232–239.
Diessner J, Wischnewsky M, Stüber T, et al. Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer. BMC Cancer 2016; 16: 307.
Gasmi M, Hooker RW, Maaouia GB, et al. The effects of intermittent fasting on markers of health: A narrative review. Medical and Pharmaceutical Journal 2023; 2: 121–133.
Gong Y, Zhang J, Ji P, et al. Incidence proportions and prognosis of breast cancer patients with bone metastases at initial diagnosis. Cancer Med 2018; 7: 4156–4169.
Harries M, Taylor A, Holmberg L, et al. Incidence of bone metastases and survival after a diagnosis of bone metastases in breast cancer patients. Cancer Epidemiol 2014; 38: 427–434.
Huang J-F, Shen J, Li X, et al. Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study. Ann Transl Med 2020; 8: 482.
Kreutzfeldt J, Rozeboom B, Dey N, et al. The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies. Am J Cancer Res 2020; 10: 1045–1067.
Lorange J-P, Ramirez Garcia Luna J, Grou-Boileau F, et al. Management of bone metastasis with zoledronic acid: A systematic review and Bayesian network meta-analysis. J Bone Oncol 2023; 39: 100470.
Ryan C, Stoltzfus KC, Horn S, et al. Epidemiology of bone metastases. Bone 2022; 158: 115783.
Saltiki K, Simeakis G, Karapanou O, et al. Metastatic medullary thyroid carcinoma (MTC): disease course, treatment modalities and factors predisposing for drug resistance. Endocrine 2023; 80: 570–579.
Shaaban SM, Gaber Z, Semary S, et al. Impact of Vitamin B12 on outcome of Early Stage Luminal A and B Breast Cancer, single center experience. Medical and Pharmaceutical Journal 2023; 2: 17–27.
Solomayer EF, Diel IJ, Wallwiener D, et al. Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer. Br J Cancer 1997; 76: 812–818.
Tsukamoto S, Kido A, Tanaka Y, et al. Current overview of treatment for metastatic bone disease. Curr Oncol 2021; 28: 3347–3372.
Vaka AR, Soni B, Reddy S. Breast cancer detection by leveraging Machine Learning. ICT Express. Epub ahead of print 2020. DOI: 10.1016/j.icte.2020.04.009.
Weitsman G, Barber PR, Nguyen LK, et al. HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status. Oncotarget 2016; 7: 51012–51026.
Xiong X, Wang J, Hu S, et al. Differentiating between multiple myeloma and metastasis subtypes of lumbar vertebra lesions using machine learning-based radiomics. Front Oncol 2021; 11: 601699.
Yang Y, Ma Y, Sheng J, et al. A multicenter, retrospective epidemiologic survey of the clinical features and management of bone metastatic disease in China. Chin J Cancer 2016; 35: 40.
Yazdani A, Dorri S, Atashi A, et al. Bone metastasis prognostic factors in breast cancer. Breast Cancer (Auckl) 2019; 13: 1178223419830978.
Yin L, Chen G-L, Xiang Z, et al. Current progress in chimeric antigen receptor-modified T cells for the treatment of metastatic breast cancer. Biomed Pharmacother 2023; 162: 114648.
Yousefi M, Nosrati R, Salmaninejad A, et al. Organ-specific metastasis of breast cancer: molecular and cellular mechanisms underlying lung metastasis. Cell Oncol 2018; 41: 123–140.
Yuan X, Qian N, Ling S, et al. Breast cancer exosomes contribute to pre-metastatic niche formation and promote bone metastasis of tumor cells. Theranostics 2021; 11: 1429–1445.
Zeng Y, Cai F, Wang P, et al. Development and validation of prognostic model based on extragastric lymph nodes metastasis and lymph node ratio in node-positive gastric cancer: a retrospective cohort study based on a multicenter database. Int J Surg 2023; 109: 794–804.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 International Journal of Health and Medicine
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
